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ABSTRACT
Protein-Protein Interactions (PPIs) play a very important role in biological functions and
therefore the inhibition of specific Protein-Protein Interactions has a huge therapeutic value.
The most successful small molecular PPIs inhibitors do not fit with the prevalent ‘Rule of
Five’ drug profile. To overcome the disadvantages of small molecular PPIs inhibitors, peptide
based PPIs inhibitors were developed. Herein we describe the development of a new class of
peptidomimetics AA-peptides. The AApeptides were designed based on chiral PNA
backbone. Substitution of nucleobases yields AApeptides that are resistant to proteolysis and
capable of mimicking peptides. Two types of AApeptides were discussed in this dissertation
“α-AApeptides” and “γ-AApeptides”. The AApeptides were shown to disrupt p53/MDM2
protein-protein interaction and tomimic fMLF tripeptide to target G protein-coupled formyl
peptide receptors (FPRs). Moreover, the lipidated α-AApeptides can mimic the structure and
function of natural antimicrobial lipopeptides and show broad-spectrum activity against both
Gram-positive and Gram-negative bacteria. Lastly I have designed and synthesized a serials
of phosphopeptides to disrupt cancer related STAT3-STAT3 dimerization.
1CHAPTER 1: INTRODUCTION
1.1 Peptides and Peptidomimetics
Protein-Protein Interactions (PPIs) play a very important role in biological functions
including gene expression, cell growth, proliferation, nutrient uptake, morphology, motility,
intercellular communication and apoptosis.1 Thus the inhibition of specific Protein-Protein
Interactions has a huge therapeutic value.2 Traditionally, the pharmaceutical industry mainly
focuses on small molecular drugs. In the past years, more and more small molecular PPIs
inhibitors were discovered.3, 4, 5 However the most successful small molecular PPIs inhibitors
do not fit with the prevalent ‘Rule of Five’ drug profile. Instead they are larger, more
hydrophobic, less hydrogen bonds, have lower ligand efficiency values.2, 6 To overcome the
disadvantages of small molecular PPIs inhibitors, peptide based PPIs inhibitors were
developed. The most effective way to discover peptide based PPIs inhibitors is their
derivation of the interface of their native protein-protein interactions.2 Beside the natural α-
peptide-based PPI inhibitors, non-natural peptide mimics, ‘peptidomimetics’, were developed
to mimic α-peptide-based PPI inhibitors.7 These non-natural peptidomimetics are designed to
mimic peptide primary structure through the use of unnatural backbones. These
peptidomimetics include peptoids,8 β-peptides,9, 10 - and -peptides,11, 12 oligoureas,13
azapeptides,14, 15 -aminoxy-peptides,16 sugar-based peptides,17, 18/β-peptides,19, 20
polyamides,21 and phenylene ethynylenes.22
21.2 AApeptides
Based on a modified N-(2-aminoethyl)-amino acid backbone from chiral peptide nucleic
acids (PNAs)23, 24, a new family of chemically diversity peptide mimics was developed in our
lab. This new peptidomimetics was termed “AApeptides” because they are comprised of N-
aminoethyl amino acids (Figure 1.1). Our goal was to develop novel drug candidates or lead
compounds based on our AApeptides.
Figure 1.1 Structures of α-Peptides and the corresponding AApeptides
1.3 Outline of the dissertation
In this dissertation, we will discuss the design and synthesis of different AApeptides and
apply them to different target.
In chapter 2, we designed and synthesized a new class of peptidomimetics termed “α-
AApeptides”. The preliminary results showed these α-AApeptides can disrupt p53/MDM2
protein-protein interaction and also demonstrated their superior stability against proteolysis.
α-Peptides
α-AApeptides
γ-AApeptides
3In chapter 3, we developed a series of lipidated α-AApeptides. These ipidated α-
AApeptides showed significant antimicrobial activities against both gram-positive and gram-
negative bacterial.
Chapter 4 summarized the design, synthesis and characterization of fMLF-mimicking
AApeptides.
In chapter 5, we designed and synthesized a serials of phosphopeptides to inhibit
STAT3-STAT3 dimerization.
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5CHAPTER 2: DESIGN AND SYNTHESIS OF AAPEPTIDES: A NEW CLASS OF
PEPTIDE MIMICS
Note to Reader
This chapter has been previously published in Bioorg. Med. Chem. Lett. 2011, 21, 1469 –
1471 and have been reproduced with the permission of RSC publishing. The Appendix B
summarises the publishing rights. The following authors have contributed to the work
published- Yaogang Hu, Xiaolong Li, Said M. Sebti, Jiandong Chen, and Jianfeng Cai.The
first author Yaogang Hu was responsible for the synthesis and charcterization of the buiding
blocks and oligomers. Xiaolong Li helped in testing the inhibition of p53/MDM2 protein-
protein interaction by the ELISA. Said M. Sebti, Jiandong Chen, and Jianfeng Cai served as
mentors .
2.1 Introduction
The creation and development of non-natural peptide mimics, or so called
“peptidomimetics”, has become an area of high interest in bioorganic and chemical biology.1
Examples of these sequence-specific oligomers include peptoids,2 β-peptides,3, 4, 5 - and -
peptides,6, 7, 8 oligoureas,9, 10 azapeptides,11, 12 -aminoxy-peptides,13 sugar-based peptides,14,
15 /β-peptides,16, 17 polyamides,18 and phenylene ethynylenes.19 These peptidomimetics are
designed to mimic peptide primary structure through the use of unnatural backbones. They are
often stable against proteolysis, and are believed to have reduced immunogenicity and
improved bioavailability compared to peptides.20 They have displayed interesting structures
6and functions, and have begun to find some important biomedical applications.21, 22
Nonetheless, the applications of peptidomimetics are still very limited, partially hampered by
the availability of frameworks.22 A wide range of new peptide mimics with new structures and
functions are urgently needed to be explored.17, 22 Such new peptide mimics are increasingly
important for the generation of new focused library for drug discovery, design of potential
therapeutics by disrupting protein-protein interactions or inhibiting enzyme activities, and
design of novel antimicrobial peptidomimetics, etc.
In the attempt to search peptidomimetics with novel frameworks, herein we propose a
family of chemically diverse peptide mimics based on a modified N-(2- aminoethyl)-amino
acid backbone from chiral PNAs.23, 24 To the best of our knowledge, such sequence-specific
peptide mimics have not been reported to mimic protein/peptide functions. They are termed
“AApeptides” because they are comprised of N-acylated-N-aminoethyl amino acids (Figure
2.1).
Figure 2.1 Structures of an -peptide and a corresponding AApeptide
Compared to natural α-peptides, the repeating unit of the AApeptide backbone is
comparable to two adjacent residues of α-peptide because it contains two side chains, one
of which is an α-amino acid side chain, while the other comes from a carboxylic acid
residue on the adjacent tertiary amide nitrogen. As a result, AApeptides are projecting
identical number of side functional groups as conventional peptides with same length of
-peptide
AApeptide
7backbones. Similar to natural peptides, all the nitrogen atoms on the AApeptide backbone
have formed either secondary or tertiary amide bonds. Such AApeptides are designed in a
way so that they can be efficiently synthesized and easily derivatized, while potentially
keep the structural and functional properties of conventional peptides. It is important to
note that because AApeptide and peptide backbones are different, their hydrogen bonding
properties and conformational flexibility (AApeptides are expected to have much more
conformations due to the higher flexibility of backbones and the existence of cis/trans
conformations of N,N-disubstituted amide bonds) are not identical. Direct translation of
sequences from peptides into AApeptides may not exhibit the same bioactivity since their
conformations are directly related to their functions.
2.2 Methods and results
The synthesis of AApeptide sequences is very simple and highly efficient by
assembling AApeptide building blocks on solid phase (Figure 2.2), which is similar to
standard solid phase synthesis of conventional peptides.
AApeptide building blocks can be prepared readily using low cost commercial
available agents. In this basic process, Fmoc-amino ethyl aldehyde reacts with amino acid
esters to form secondary amines, which are subsequently acylated with carboxylic acids.
Deprotection of the coupling products gives the desired AApeptide building blocks.
Starting materials are readily available, and the potential of rapidly forming AApeptide
derivatives with a wide variety of side chains is almost limitless because there are thousands
of carboxylic acids available for acylation.
8Figure 2.2 Typical synthesis of an AApeptide building block. a) Fmoc-amino ethyl aldehyde,
NaBH3CN, CH3OH, overnight. b) R1CH2COOH, DhBtOH/DIC, overnight. c) Pd/C, H2, EtOAc
for A; 50% TFA/CH2Cl2 for B.
To demonstrate the facile synthesis and potential bioactivity of AApeptides, as a proof-
of-principle, we designed four AApeptide sequences to target p53/MDM2 protein-protein
interaction (Figure 2.3) by preliminary computer modeling (Figure 6.2, supporting
information), and synthesized them on the solid phase.
These sequences were purified by HPLC with over 95% purity. For convenience, in
each AApeptide residue in a sequence, the amide side chain is given the same designation
corresponding to the cognate amino acid, with the prime ′, and keeping the name of the
chiral side chain same as the -amino acid. These sequences were then tested for the
inhibition of p53/MDM2 protein-protein interaction by the ELISA assay25 (Table 2.1).
9Figure 2.3 AApeptide sequences synthesized for p53/MDM2 disruption
The AApeptides also exhibit excellent selectivity. AApeptide AA1 is a poor inhibitor of
p53/MDM2 interaction, while AA2 and AA3 are weaker inhibitors compared to AA4.
Structure-activity relationship (SAR) is consistent to previous reported studies.26 Phe, Typ and
Leu functionalities are necessary for strong binding, which are absent in AA1 but present in all
other sequences. Compare AA2 to same-length AA1, the change of Leu into Val decreases the
10
activity at least 10-fold. Second, it seems longer sequences have better activities, as seen for
AA4 and AA2, possibly due to the higher stability of the backbone conformations. Side chains
that are not involved in the recognition of MDM2 hydrophobic binding cleft also play a very
important role for the overall interactions, since AA3 and AA4 differ for only one residue. In
AA3, the Phe′ side chain may clash with residues of MDM2 near the edge of the binding
domain, which probably increases its binding energy to MDM2. Detailed SAR study for
sequences with a variety of lengths and distribution of functional groups along the AApeptide
backbone is currently ongoing, which could further shed light on the rational design of
AApeptide library for drug discovery.
Table 2.1 ELISA results of AApeptides for the disruption of p53/MDM2
AApeptides IC50 (M)
AA1. Val’-Ala-Ala′-Phe-Ser′-Trp-Ala′-Val  1000
AA2. Ala’-Phe-Ser′-Trp-Ala′-Leu-Ala′-Ala 120  10
AA3. Ala′-Ala-Ala′-Phe-Ser′-Trp-Phe′-Leu-Ala′-Ala 120  16
AA4. Ala′-Ala-Ala′-Phe-Ser′-Trp-Ala′-Leu-Ala′-Ala 38  8
p53-derived peptide (Ac-QETFSDLWKLLP) 8.7 26
A significant disadvantage of peptides is their susceptibility to proteolysis. To assess the
sensitivity of AApeptides to enzymatic hydrolysis, we incubated a representative sequence
AA3 with chymotrypsin, trypsin, and pronase (0.1 mg/ml) respectively in 100 mM pH 7.8
ammonium bicarbonate buffer for 24 h. The reaction mixtures were analyzed by HPLC by
comparing their retention time and integration to those of the starting material. The results (see
supporting information) show that AApeptide AA3 is highly resistant to proteolysis. After 24
h incubation, AA3 was not cleaved by the enzymes.
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2.3 Conclusions
We have designed a new family of peptide mimics-AApeptides and described a simple
approach for their efficient synthesis based on N-acylated-N-Fmoc-amino ethyl amino acid
building blocks. The potential of AApeptide diversification by introducing a wide variety of
side groups is substantial. The preliminary results demonstrated their superior stability against
proteolysis, significant bioactivity and excellent selectivity toward p53/MDM2 protein-protein
interaction. The development of such sequence-specific AApeptides may expand the
applications of peptidomimetics in the areas of biomedical and material sciences, such as
modulation of protein-protein interactions, and generation of focused library for drug discovery,
etc. We are currently carrying out systematic studies to probe structural requirements for
AApeptides to adopt predicted conformations using 2D-NMR, Circular Dichroism (CD) and
X-ray crystallography. Optimization of AApeptide sequences through rational design to
achieve more potent bioactivity towards p53/MDM2 and other proteins/nucleic
acids/carbohydrates interactions are also under investigation.
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3.1 Introduction
Antimicrobial peptides (AMPs) are found in most living organisms as an integral
component of their innate defense against invading pathogens.1, 2 Unlike conventional
antibiotics that target specific substrates involved in bacteria’s metabolism, AMPs are believed
to kill bacteria via a nonspecific interaction with its membrane, which has a less chance to
induce the development of resistance by bacteria.1, 2 Short cationic amphiphilic AMPs tend to
interact with the negatively charged phospholipids on the bacterial membrane, which accounts
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for their selectivity for bacteria against eukaryotic cells in which the membranes are more
zwitterionic.3, 4 Due to their selectivity for bacteria, low propensity for development of drug
resistance, and a broad-spectrum antimicrobial potency, AMPs are considered an emerging
class of antimicrobial agents.1, 2, 3 Nevertheless, the therapeutic application of AMPs is impeded
by their intrinsic instability in the context of proteolytic degradation.1, 2 Bactericidal
peptidomimetics comprising of unnatural amino acids were thereby developed to circumvent
the drawbacks of AMPs, which are protease-resistant and of improved bioavailability.5 In
recent years, several peptidomimetic analogs of AMPs, such as β-peptides,6, 7, 8, 9 arylamides,10,
11 and peptoids,3, 12, 13 have received significant research interests.
Lipidated peptides such as polymyxin B14 and Daptomycin15 are lipo-antibiotics, which
possess fatty acid tails that are integral to their bactericidal activities. It has been shown that
attachment of saturated linear fatty acids to peptide termini greatly enhanced AMPs’
antimicrobial activities, towards both Gram-positive and Gram-negative strains.16, 17, 18, 19 More
recently, short peptoid mimetics alkylated with lipids of 10 or 13 carbons were demonstrated
to bear improved selectivity, without losing any antimicrobial activities.13 It was suspected that
lipid alkylation improved the hydrophobicity of charged peptides,18 thereby facilitates the
interaction with cytoplasmic membranes.18 We have recently developed a novel class of
peptidomimetics based on the α-chiral PNA backbone, which is termed “α-AApeptides”.
Besides their resistance to proteolysis, α-AApeptides also feature limitless diversification,
which makes it a promising agent for biological applications, such as the inhibition of protein-
protein interaction.20 Notably, a 7-mer α-AApeptide α1 was identified to kill both Gram-
negative and Gram-positive bacteria and fungi, with a minimum hemolytic activity.21 To
further explore the potential antimicrobial application of α-AApeptide, as well as to develop
shorter peptide mimics for synthetic and pharmacological benefits,22, 23, 24, 25, 26 we now report
our efforts in the development of lipidated antimicrobial α-AApeptides. Recently we reported
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lipidated antimicrobial γ-AApeptides,27 a closely related class of peptidomimetics to α-
AApeptides. Therefore, it will be very interesting to find out the impact of lipidation of α-
AApeptides on their antimicrobial activity.
3.2 Methods and results
The design of α-AApeptides follows the previously demonstrated principle 21, 28 that a
global distribution of cationic and hydrophobic side chains is key to antimicrobial activity; and
a defined secondary structure is unnecessary, as long as side groups can segregate into
hydrophobic and cationic clusters upon interaction with bacterial membranes. As such, α-
AApeptide building blocks were designed to be either amphiphilic or cationic, which were
assembled and alkylated with C-16 hydrophobic lipid tail at the N-terminus of the oligomers
(Figure 3.1).  The synthesis of lipidated α-AApeptides was carried out following previous
reported protocol,29 and the N-terminus of the last building block was capped with palmitic
acid to achieve a final lipidation.
Lipidated α-AApeptides were tested for their antimicrobial activities against Gram-
positive B. subtilis, S. epidermidis, E. faecalis, S. aureus, and Gram-negative E. Coli, K.
pneumoniae, P. aeruginosa, and fungus C. albicans, many of which are multi-drug resistant
strains. For comparison purpose, the previously reported most active linear α-AApeptide α121
as well as Pexiganan, a phase III antimicrobial peptide drug candidate,3, 13, 30, 31 were employed
as positive controls.
Being very short lipidated α-AApeptides, NA-75 and NA-77 appeared to be ineffective
against Gram-negative strains; however, they are very active against Gram-positive strains and
fungus C. albicans (Figure 3.2). Meanwhile, they almost had no hemolytic activity (Table 3.1),
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which augments their potential development as antifungal agents and antibacterial agents to
treat Gram-positive bacterial infections.
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Figure 3.1 The structures of synthesized lipidated α-AApeptides
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The activity towards Gram-negative bacterial strains was achieved by introducing
additional α-AApeptide building blocks. For instance, NB-119-1 and NB-127 are 3-mer
oligomers. Although NB-127 was still not active towards Gram-negative bacteria, NB-119-1
displayed an adequate activity against both Gram-positive and Gram-negative strains.  In
addition, NB-119-1 possessed a much lower toxicity (weaker hemolytic activity) than NB-127.
Further, the lipidated 3-mer NB-119-1 already displayed an improved activity than the linear
7-mer α121 made from the same building block, indicating that lipidation significantly
enhanced the antimicrobial activity of α-AApeptides. Broad-spectrum and potent
antimicrobial activity was further improved by the addition of more α-AApeptide building
blocks. NB-119-2, NB-119-3 and NB-123 are all active towards all tested strains, and are more
potent than both Pexiganan and linear α1.  Hence, a longer sequence of cationic charges and
hydrophobic groups can lead to improved overall activity, which is similar to previous
observations.21 They are also selective because none of them has toxicity towards red blood
cells and mammalian cells (Table 3.1)
As AMPs employ membrane disruption mechanism to circumvent drug-resistance
occurring in the use of conventional antibiotics for the treatment of bacteria, it is essential to
evaluate whether lipidated α-AApeptides can also adopt the similar bactericidal mechanism.
As such, one the most potent lipidated α-AApeptide, NB-119-2 was assessed by fluorescence
microscopy study. A serials of fluorescence study was carried out to prove the lipidated α-
AApeptide, NB-119-2 can disrupt the bacterial membrane which is very important for drug
resistance. The details of experiments are described as below.
.
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Table 3.1 The antimicrobial and hemolytic activities of oligomers. The microbial organisms used are C. albicans (ATCC 10231), E. Coli
(JM109), B. subtilis (BR151), multi-drug resistant S. epidermidis (RP62A), Vancomycin-Resistant E. faecalis (ATCC 700802), Methicillin-
Resistant S. aureus (ATCC 33592), K. pneumoniae (ATCC 13383), and multi-drug resistant P. aeruginosa (ATCC 27853). The minimum
inhibitory concentration (MIC) for bacteria is the lowest concentration that completely inhibits growth after 24 h; and MIC for fungus C.
albicans is the lowest concentration that completely inhibits growth after 48 h. Pexiganan and Linear α1 were used as control. H10 is the
concentration of α-AApeptides at which 10% hemolysis was observed, and H50 is the concentration of α-AApeptides at which 50% hemolysis
was observed.
Organism
MIC (µg/mL)
NA-75 NA-77 NB-119-1 NB-127 NB-119-2 NB-119-3 NB-123 Pexiganan3,13,30,31
Linear α1
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Gram-positive
B. subtilis 2 4 2 2 4 2 4 4 2
S. epidermidis (MRSE) 10 15 8 20 10 4 10 8 10
E. faecalis (VREF) 1 3 4 10 4 4 20 32 >50
S. aureus (MRSA) 5 8 4 8 8 4 8 16 >50
Gram-negative
E. Coli >50 >50 8 >50 4 30 4 8 4.5
K. pneumoniae >50 >50 >50 >50 8 8 20 8 >50
P. aeruginosa >50 >50 20 >50 12 8 10 8-16 >50
Fungus
C. albicans 2 2 3 >50 4 20 10 124 20-30
Hemolysis (H10/H50) >500/>500
>500/
>500 50/ 300 15/ 150 20/250 40/ 400 100/ >500 181/ 495 400/>500
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Both gram-negative E. coli and gram-positive B. subtilis were treated with NB-119-2, and
then stained by 4’, 6-diamidino-2-phenylindole (DAPI) which stains all bacterial cells, and
propidium iodide dye which selectively penetrates dead or injured cells with damaged
membranes32, 33 (Figure 3.2). Without the incubation with NB-119-2, both E. coli and B.
subtilis were stained in blue by DAPI, while little of them had PI staining (red fluorescence).
However, both bacteria showed a strong red fluorescence as a result of PI staining after
incubation with NB-119-2 for 2 h, suggesting the significant membrane damage. The
aggregation of injured or dead cells in both oligomer-treated E. coli and B. subtilis is consistent
to previous report,32 which indicates a loss of membrane potential. Collectively, the lipidated
α-AApeptide effectively inhibits bacteria, via a membrane-lysis mechanism similar to natural
antimicrobial peptides, but different from lipo-antibiotics such as Polymyxin B34 and
Daptomycin35 , which are only either active against Gram-negative or Gram-positive bacteria,
respectively.
3.3 Conclusions
Taken together, we have reported, for the first time, a series of lipidated α-AApeptides that
feature significant antimicrobial activities.  Through preliminary structure and activity studies,
several short lipidated α-AApeptides, such as NB-123, NB-119-2, and NB-119-3, have been
identified to have comparable or even superior activity and selectivity to the current clinical
candidate pexiganan, as well as the previously reported linear α-AApeptide α1.  Due to the
activity enhancement by lipidation, these potent oligomers have a relatively shorter backbone
than the traditional linear α1. Mechanistic study shows that these lipidated α-AApeptides can
mimic AMPs by disrupting bacterial membranes, which potentially circumvents drug-
resistance. Among all the tested lipidated and regular α-AApeptides, NB-123, NB-119-2 and
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NB-119-3 bear the most potent and broad-spectrum antimicrobial activity and the highest
selectivity. They are better than pexiganan in terms of the overall performance, suggesting that
NB-123, NB-119-2 and NB-119-3 could be the promising novel antibiotic candidates in the
future.
Figure 3.2 Fluorescence micrographs of E. coli and B. subtilis treated with 10 µg/ml of NB-
119-2 for 2 h. a1-a4, E. coli. B1-b4, B. subtilis. A1 and b1, control, no treatment, DAPI
stained; a2 and b2, control, no treatment, PI stained; a3 and b3, NB-119-2 treatment, DAPI
stained; a4 and b4, NB-119-2 treatment, PI stained.
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4.1 Introduction
Neutrophils are one of the key components of innate immune system1 as they play an
essential role in host defense against bacterial and fungal infections.2 Their responses can be
modulated by the interaction between chemoattractants and cell surface receptors.3 For instance,
peptides bearing N-formyl-methionine residue, either derived from bacteria or mitochondria in
eukaryotic cells, are potent chemoattractants of neutrophils.4, 5 They bind to a class of G
protein-coupled formyl peptide receptors (FPRs) on the membrane of neutrophils, triggering
intracellular signaling pathways that enhance the bactericidal activities of phagocytes including
the migration of phagocytic cells towards the sites of inflammation as well as superoxide
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production.2, 6 Among these peptides, N-formyl-Met-Leu-Phe (fMLF), the smallest formyl
peptide that binds to FPR1 with high affinity, has been widely used as the reference agonist to
study the GPCR-mediated host defense and biochemical signaling pathways in phagocytes.6, 7
Studies indicate that fMLF plays a critical role in the regulation of a variety of physiological
functions, and show great promise for the treatment of bacterial infection, HIV, inflammation,
and cancer.8 Due to its biological interest and translational potential, there has been an
extensive effort in developing fMLF analogues as potential molecular probes as well as
therapeutic agents.9
We have recently developed a new class of peptidomimetics termed “AApeptides”, as they
are based on N-acylated-N-aminoethyl amino acid residues (Figure 4.1)10 derived from chiral
PNA backbones. Half of the side chains in an AApeptide are derived from amino acids, and
the other half of side chains come from any acylating agents including carboxylic acids,11 acyl
chlorides,12 and sulfonyl chlorides.11 As such, the potential for the introduction of chemically
diverse functional groups into AApeptides is limitless. According to the relative positions of
side chains, AApeptides are classified into two subfamilies: α-AApeptides and γ-AApeptides.
Both α-AApeptides and γ-AApeptides have exhibited high resistance against proteolytic
degradation.10, 13, 14 By recapturing the structure and function of bioactive peptides, these
AApeptides have found a wide variety of applications such as development of antimicrobial
agents mimicking host defense peptides,15 Tat and RGD mimetics,14, 16 and for protein/peptide
recognition.10 These endeavors have demonstrated the potential applications of AApeptides in
biomedical sciences. Thus, we believe it is of interest to evaluate the ability of AApeptides for
their mimicry of fMLF, so as to develop novel therapeutic agents in the future. In this study, a
focused library of AApeptides was designed, synthesized and tested for their ability to activate
neutrophils through FPRs.
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Figure 4.1 The structure of α-peptides, α-AApeptides and γ-AApeptides. In both α-
AApeptides and γ-AApeptides, half of side chains are introduced through acylation, while the
other half of side chains are chiral and derived from amino acids.
4.2 Methods and discussion
As shown in Figure 4.2, AApeptides 1-7 were designed to mimic the formyl peptide fMLF.
These sequences contain either an N-formyl methionine or an N-formyl norleucine which is
known to be critical for the agonistic activity at FPRs.6, 9, 17 In addition, one AApeptide building
block was also included to mimic the leucine and phenylalanine residues in fMLF. Both α-
AApeptides (1 and 2) and γ-AApeptides (3-7) were designed, synthesized and tested for their
activity at FPRs.
Figure 4.2 The structures of fMLF and AApeptides
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The synthesis of AApeptides was carried out following our reported procedures on the
solid phase (Figure 4.3).18, 11, 12, 19 In brief, α-AApeptides 1 and 2 were obtained by
incorporating the α-AApeptide building block directly in the synthesis.10 γ-AApeptides 3-7
were synthesized by using alloc-protected γ-AApeptide building blocks.12, 19 The formyl group
on the N-terminus of methionine and norleucine in the sequences was added following a
published protocol.9 Briefly, isobutyl chloroformate and formic acid were mixed at 1:1 ratio in
DCM, and then cooled down to at 0 °C, to which 1 equiv. NMM (N-methylmorpholine) was
added. The resulting solution was added to resin and allowed to react for two hours. The
procedure was repeated twice. The AApeptides were obtained by HPLC purification after
cleavage from solid support by TFA.
To assess the ability of these peptidomimetics to mimic the function of the fMLF peptide,
we first tested their efficacy in the induction of calcium mobilization in human FPR1
transfected RBL-2H3 cells. As shown in Figure 4.4, fMLF is a potent activator of calcium
mobilization, and it takes effect at the concentrations as low as 1 nM. It seems that α-
AApeptides cannot mimic fMLF because both 1 and 2 do not exhibit capability to induce
calcium mobilization. This may be explained by the relative positions of side chains on α-
AApeptides. The aliphatic side chains in 1 and 2 are introduced via acylation, and they are next
to the chiral aromatic side chains. They were designed to mimic the Leu-Phe dipeptide residues.
However, since these side chains are too close to each other, their spatial relationship is quite
different from that of the Leu-Phe dipeptide residues in the model peptide. As a result, they
failed to mimic the functions of Leu-Phe effectively and in fact were not active at all. However,
a few γ-AApeptides showed good activity in calcium mobilization assays. It is possible that in
γ-AApeptides, the spatial orientation of side chains is more similar to regular peptides than in
α-AApeptides.
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Figure 4.3 a, synthesis of α-AApeptides 1 and 2; b, synthesis of γ-AApeptides 3-7
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Figure 4.4 AApeptide-induced activation of calcium mobilization in human FPR1 transfected
RBL cells
Among them, 1, 2, 5 and 6 did not display any activity under tested condition. However,
3, 4 and 7 exhibited dose-dependent function in calcium mobilization assays. 4 became
effective at the concentration of 50 µM, while 3 and 7 started to stimulate calcium mobilization
at 2 µM. At 50 µM, 3 had efficacy similar to fMLF at 10 µM. Surprisingly, at the concentration
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of 10 µM, 7 was almost 2-fold as effective as fMLF at the same concentration, although at
lower concentrations it was less potent. Although the mechanism is elusive and a more detailed
study is needed in the future, this unusual activity-boosting maybe explained by the
multivalency theory. It is known that multivalent ligands are much more effective in receptor
signaling than monomeric ligands because these ligands increase avidity and induce positive
cooperativity when interacting with receptors.20 We hypothesize that, although 7 is less
effective than fMLF at low concentrations, it may aggregate at cell membranes at higher
concentrations. Such aggregation, even non-covalent, may lead to multivalent effect, thereby
boosting its activity dramatically. The structure-activity relationship of these γ-AApeptides is
also somewhat different from peptide-based fMLF mimetics. It is known that replacement of
the methionine with norleucine in fMLF does not reduce bioactivity of the peptide;21
nevertheless, we observed that 4 is less effective than 3. Interestingly, 6 is not active, but 7 is
the most potent molecule identified so far in this group. These results suggest that all three side
chains in AApeptides are important for their activity, and any one of them has to have correct
orientation for all side chains in order to be active. Since these AApeptides are short and
presumably do not have any secondary structures, a small change in one side chain may affect
the overall structure dramatically. These findings may also provide insight into the
development of more potent fMLF mimetics in the future.
The selectivity of these γ-AApeptides was further evaluated by testing their capability in
the induction of calcium mobilization in human FPR2-transfected RBL cells. The FPR2-
specific synthetic peptide W-peptide (WKYMVM) was used as a positive control.3 It is known
that fMLF is more selective towards FPR1 than FPR2, thus it is interesting to know if fMLF-
mimicking γ-AApeptides have the similar selectivity. As shown in Figure 4.5, W-peptide
exhibited potent activity in calcium mobilization assay. Sequences 1, 2, 5 and 6, which were
inactive toward FP1, were also inactive toward FPR2 (data not shown). Interestingly, the other
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three γ-AApeptides 3, 4 and 7, which were active at FPR1, were also active at FPR2. However,
they have different preference for the two receptors. While compound 4 showed the weakest
activity to induce FPR1-mediated calcium mobilization, it displayed most potent activity
towards FPR2. In contrast, both 3 and 7 were more selective for FPR1. At 10 µM, 7 was even
more efficacious than fMLF at FPR1, however, it did not have any activity towards FPR2 in
calcium mobilization assay at this concentration. This is consistent with previous findings that
subtle changes in the short peptide/peptidomimetic sequences can affect the selectivity of
compounds towards FPR1 and FPR2.3
Figure 4.5 γ-AApeptide-induced activation of calcium mobilization in human FPR2
transfected RBL cells. Data shown are representative of three independent experiments.
In addition to calcium mobilization, it is known that binding of fMLF to FPR1 activates
the MAP kinases ERK1 and ERK2 in human neutrophils.3 To investigate whether the lead
AApeptides has the ability to simulate this signaling pathway, RBL cells transfected to express
human FPR1 were treated with either fMLF or γ-AApeptides 3, 4 and 7. ERK (including both
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ERK1 and ERK2) activation was determined using an antibody against the phosphorylated
MAP kinases. Fig.4.6 shows that the ability of γ-AApeptides for the activation of the ERK
signaling pathway is highly consistent to their capability to induce calcium mobilization shown
in Figure 4.4.
Figure 4.6 Activation of ERKs by fMLF and γ-AApeptides 3, 4 and 7 in human FPR1-
transfected RBL cells. These cells were stimulated with fMLF peptide (1 µM, upper-left), γ-
AApeptides 3 (10 µM, upper-right), 4 (10 µM, lower-left) and 7 (10 µM, lower-right),
respectively. After various time intervals the cells were harvested and the phosphorylated
ERKs were determined by Western blotting with anti-phospho-ERK antibodies. Data shown
are representative of three independent experiments.
As shown in Figure 4.6, cells responded to fMLF with rapid tyrosine phosphorylation of
ERK, which was consistently observed in previous studies.3 At the tested concentration of 10
µM, 4 failed to show any capability to induce ERK phosphorylation. However, following
stimulation with either 3 or 7, the rapid and potent response was observed at 1 min and peaked
between 2 and 5 min. The ability of γ-AApeptides to activate the ERK signaling pathway
further demonstrates their potential to mimic fMLF peptide.
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Figure 4.7 a, effects of the lead γ-AApeptides on ROS production in differentiated HL-60
cells. b, effects of the lead γ-AApeptides on chemotaxis of differentiated HL-60 cells. Data
shown are representative of three independent experiments.
In addition to activation of calcium mobilization and the ERK signaling pathway, fMLF
triggers chemotaxis and ROS production, which are key features of host defense in response to
bacterial infection.4 To assess whether γ-AApeptides can mimic these functions of fMLF, we
investigated the ability of the lead γ-AApeptides 3, 4 and 7 for the activation of chemotaxis
and ROS production. As shown in Figure 6, although less potent than fMLF, 3 and 7 can
effectively trigger the production of ROS (Figure 4.7 a) and induce chemotaxis (Figure 4.7 b).
Consistent to calcium mobilization and ERK activation, 7 is the most potent molecule in the
ROS production and chemotaxis assays, while 4 does not exhibit noticeable activity at
concentrations up to 10 µM.
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4.3 Conclusions
To summarize, we have designed a new class of peptidomimetics that mimic the structure
and function of fMLF. This is also the first report of AApeptides as agonists that trigger GPCR
signaling. From the focused library we synthesized on solid phase, a few AApeptides have
shown to  effectively induce calcium mobilization and Mitogen-Activated Protein Kinase
(MAPK) signal transduction pathways in FPR-transfected RBL cells. More intriguingly, at
high concentrations, certain γ-AApeptides are even more efficacious than fMLF in the
induction of calcium mobilization. Similar to fMLF, these AApeptides are much more selective
towards FPR1 rather than FPR2. Their agonistic activity is further supported by their ability to
stimulate chemotaxis and production of superoxide in HL-60 cells. These results suggest that
these fMLF-mimicking γ-AApeptides may emerge to be a new class of agents for the treatment
of a variety of diseases. As fMLF peptides with C-terminus of COOH, CONH2 and COOMe
can have different activity under different experimental conditions,22, 23 we envision that fMLF-
mimicking γ-AApeptides may behave in a similar fashion. The synthesis and evaluation of
these γ-AApeptides bearing different C-terminal functional groups are currently underway.
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CHAPTER 5: DESIGN AND SYNTHESIS OF PHOSPHOPEPTIDES AS STAT3
INHIBITOR
5.1 Introduction
STAT3 (Signal transducer and activator of transcription 3), a member of the STAT
family, is a transcription factor that mediates cytokines and growth factors-direction
transcription.1 STAT3 plays very important role in cell growth, differentiation and survival.2,
3, 4, 5 In normal condition, STAT3 is transient and tightly regulated. Stat3, binding to the
extracellular signaling proteins via its SH2 domain, is recruited to phosphotyrosine residues
and becomes phosphorylated on Tyr705. The phosphorylated stat3 dimerizes and the
activated complex is translocated to the nucleus where it acts as transcription activators.6
STAT3 dimers bind to specific DNA areas resulting in regulation of specific gene
expression.7, 8 However, many studies indicate inappropriate activation of STAT3 occurs in a
wide variety of human cancers.9 Such hyperactivation of STAT3 leads to uncontrolled cell
proliferation by activating cell cycle regulators such as c-Myc and cyclin D1, and
enhancement of cell survival by selectively inducing the expression of anti-apoptotic proteins
including Bcl-xL and survivin.10 Thus mediating STAT3 signal path ways provides a good
strategy for treating a variety of human cancers.11
SH2 domain is the functional domain of STAT3 (dimerization domain and DNA
binding domain). So most researchers focused on SH2 domain. STAT3 signaling can be
supressed by inhibition of STAT3-STAT3 dimerization or inhibition of STAT3-DNA
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binding.4, 5, 12 Untill now many peptides and peptidomimetics were developed to inhibit
STAT3-STAT3 dimerization. Turkson et al. first found that a truncated peptide sequence
Pro-pTyr-Leu-Lys-Thr-Lys, derived from the native STAT3-binding phosphopeptide, can
block STAT3-STAT3 dimerization.13 Subsequently, McMurray et al. designed more
sequences based on STAT3 SH2 binding domain and found more potent hexpetpide.14, 15,
16, 17 (Figure 5.1)
A IC50 = 290 ± 63 nM                 B   IC50 = 138 ± 8 nM
Figure 5.1 Structure and IC50 of McMurry’s compounds 17
In our lab, a serials of phosphopeptides were designed, synthesized and tested for their
ability to inhibit STAT3-STAT3 dimerization.
5.2 Methods and results
As shown in Figure 5.2, a serials of phosphopeptides were designed synthesized to
target SH2 domain of STAT3.
Before the synthesif of the phosphopeptides, Fmoc protected natural amino aicds and
some building blocks were used to synthesize the phosphopeptide sequences. The synthesis
of the building blocks was shown in Figure 5.3.
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Figure 5.2 phosphopeptide sequences synthesiezed for STAT3 inhibition
Figure 5.3 Synthesis of building blocks 18, 19
The synthesis of phosphopeptide sequences is very simple and highly efficient by
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assembling building blocks and natural amino acids on solid phase, which followed
standard Fmoc solid phase protocol. Figure 5.4 showed the example of synthesis of NB003-
55-03.
Figure 5.4 Synthsis of NB003-55-03
After standard solid phase synthesis, the phosphopeptide sequence was cleaved from
the resin by 50% TFA in DCM. Then the TFA and DCM were removed by vacuum. The
residue was dissolved in 2 mL DCM. At 0℃, 10 eq TMSI was added to the solution. The
mixture was stirred at 0℃ for 1 hour. The solvent was removed by vacuum. The product
was pufified by prepared HPLC (5% to 100% linear gradient of solvent B (0.1% TFA in
acetonitrile) in A (0.1% TFA in water) over 40 min).
Fluorescence polarization (FP) assay was used to evaluate the activity of the
phosphopeptides. FP assay was conducted based on fluorescence signal differences
between free and STAT3-bound fluorescently labeled peptide as described by Zhang et al.7
At the beginning, all the compounds was done the FP assay at the concentration of 50 M.
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Only the compounds can inhibit the the STAT3 more than 50% at the concentration of 50
M were selected to do the FP at different concentration to calculate IC50. The FP assay
results were shown in Table 5.1.
From the sturcture and results we can find that the Gln, Leu and pTyr play most important
role in the activity of the compounds. Especially compound NB003-50-02 has an IC50 12.1 M.
This compound only has Gln, Leu and pTyr. However the activity is better than most of the
compounds. Also the benzyl amide C terminal can improve the activity compared to the
isopropyl amide or carbonyl amide.
Table 5.1 FP results of phosphopeptides
phosphopeptides IC50 (M)
NB003-49-02 29.1
NB003-49-03 17.0
NB003-50-02 12.1
NB003-50-03 13.3
NB003-51-01 31.1
NB003-51-03 8.2
NB003-53-03 11.6
NB003-55-04 24.7
NB003-55-05 22.8
NB003-59-01 14.6
NB003-59-03 21.1
NB003-65-03 1.5
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5.3 Conclusions
We designed and synthesized a serials of phosphopeptides that can inhibit STAT3-STAT3
dimerization. Different building blocks was used to replace the natrual amino acid Proline. The
best compound NB003-65-03 has an IC50 1.5 M. However the cell assay showed this
compound has no cell activity. In the future prodrug compounds will be synthesized to evaluate
the cell activity.
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CHAPTER 6: SUPPORTING INFORMATION
6.1 Supporting Information for Chapter 2
6.1.1 General consideration
-amino acid esters and Knorr resin (0.66 mmol/g, 200-400 mesh) were provided by
Chem-Impex International, Inc. All other reagents and solvents were purchased from either
Sigma-Aldrich or Fisher Scientific. NMR spectra of intermediates and AApeptide building
blocks were obtained on a Varian Inova 400 instrument. AApeptides were prepared on Knorr
resin in peptide synthesis vessels on a Burrell Wrist-Action shaker. The AApeptides were
analyzed and purified on an analytical and a preparative Dionex HPLC systems, respectively,
and then dried by a Labcono lyophilizer. Molecular weights of AApeptides were identified on
a Bruker AutoFlex MALDI-TOF mass spectrometer.
6.1.2 General procedure for synthesis of building blocks
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Figure 6.1 Typical synthesis of an AApeptide building block. a) Fmoc-amino ethyl aldehyde,
NaBH3CN, CH3OH, overnight. b) R1CH2COOH, DhBtOH/DIC, overnight. c) Pd/C, H2,
EtOAc for A; 50% TFA/CH2Cl2 for B.
Typical synthesis of 2. An amino acid ester hydrochloride in 15 ml methanol in a 100
ml round bottom flask was added 1.1 equiv. of triethylamine and stirred at 0 oC for 15 min.
Stoichiometric amount of Fmoc-glycinaldehyde was added and the solution mixture was
stirred for another 30 min. 2-5 drops of acetic acid was then added followed by 2 equiv. of
NaBH3CN. The solution was stirred at 0 oC for 1 h and continued at room temperature
overnight. The solvent was then removed and 100 ml ethyl acetate and 100 ml saturated
sodium bicarbonate solution were added. The organic layer was separated and washed with
100 ml brine, dried over anhydrous sodium sulfate, and then concentrated in vacuo. Flash
chromatography using ethyl acetate/hexane 1:2 gave 2 (Rf = 0.1) as a colorless oil.
Typical synthesis of 3. Compound 2, 1.2 equiv. of DIC, Oxohydroxybenzotriazole
(ODhbt), and R1CH2COOH were stirred in 20 ml DMF overnight. The solution was then
partitioned in 100 ml ethyl acetate and 100 ml water. The organic layer was separated and
washed with water (3 100 ml) and Brine (2 100 ml), dried over anhydrous sodium sulfate,
and then concentrated in vacuo. Flash chromatography using ethyl acetate/hexane 1:3 gave 3
(Rf = 0.1) as a colorless oil.
Typical synthesis of 4.
Route A. 3 in 20 ml ethyl acetate and was added 10% Pd/C and hydrogenated at atmospheric
pressure and room temperature overnight. The solution was evaporated and the residue was
purified by flash chromatography 5-7% MeOH/CH2Cl2 to give 4 (Rf = 0.2) as a white foam
solid.
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Route B. 3 in 50 ml RB flask was added 10 ml 50% TFA/CH2Cl2 at room temperature and
then stirred 2 h. The solution was removed and the residue was purified by flash
chromatography 5-7% MeOH/CH2Cl2 to give 4 (Rf = 0.2) as a white foam solid.
6.1.3 NMR and High Resolution Mass Data
N
H
O
O
H
N
Fmoc
2a
Compound 2a. Yield 91%. 1H-NMR (CDCl3, 400 MHz) δ = 7.76 (2H, d, J = 7.6), δ  7.61
(2H, d, J = 7.6), 7.398 (2H, t), 7.312(2H, t), 5.334 (1H, s), 4.39 (2H, d), 4.23 (1H, m), 3.35-
3.20 (3H, m),  2.80-2.62 (2H, m), 1.47 (9H, s), 1.26 (3H, d, J=6.8). 13C-NMR (CDCl3,
100 MHz) δ 175.3, 156.7, 144.2, 127.8, 127.2, 125.3, 120.1, 81.3, 66.8, 57.2, 47.5, 47.3, 41.2,
28.3, 19.4. HR-ESI: [M+H]+ cacl: 411.22783, found: 411.22796.
N
H
O
O
H
N
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2b
Compound 2b. Yield 86%. 1H-NMR (CDCl3, 400 MHz) δ 7.69 (2H, d, J = 7.2), 7.52 (2H, d,
J = 7.2), 7.326 (2H, t), 7.242-7.121(7H, m), 5.09 (1H, s), 4.29 (2H, d), 4.14 (1H, m), 3.28
(1H, m),  3.12 (2H, m), 2.80-2.7 (3H, m), 2.50 (1H, m), 1.47 (9H, s). 13C-NMR (CDCl3, 100
MHz) δ 174.1, 156.7, 144.3, 141.5, 137.8, 129.5, 128.5, 127.8, 127.2, 126.8, 125.3, 120.2,
81.6, 66.8, 63.1, 47.5, 47.3, 40.9, 40.0, 28.2. HR-ESI: [M+H]+ cacl: 487.25913, found:
487.25914.
N
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Compound 2c. Yield 72%. 1H-NMR (CDCl3, 400 MHz) δ 8.12 (1H), 7.76 (2H, d, J = 7.2),
7.59-7.57 (4H, m), 7.43-7.38(4H, m), 7.32-7.23(8H, m), 7.16 (2H), 5.17 (1H, s), 5.06 (2H),
4.36 (2H, d, J=6.4), 4.22 (1H, m), 3.67 (1H, m), 3.26-3.17 (4H, m),  3.15 (2H, m), 2.80-2.63
(2H, m), 1.64 (9H, s). 13C-NMR (CDCl3, 100 MHz) δ 174.6, 156.7, 149.8, 144.3, 141.5,
135.7, 135.6, 130.6, 128.8, 128.6, 128.4, 127.9, 127.3, 125.3, 124.7, 124.3, 122.8, 120.2,
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119.2, 116.2, 115.6,  83.8, 66.997, 66.933, 61.6, 47.6, 47.5, 41.0, 29.4, 28.4. HR-ESI:
[M+H]+cacl:660.30681, found:660.30617.
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Compound 2d. Yield 87%. 1H-NMR (CDCl3, 400 MHz) δ  7.76 (2H, d, J = 7.6), 7.60 (2H,
d, J = 7.6), 7.41 (2H, t), 7.32 (2H, m), 5.35 (1H, m), 4.36 (2H, d, J=6.0), 4.24 (1H, t),
3.33(1H, m), 3.18 (1H, m),  2.82 (2H, m), 2.56 (1H, m), 1.90 (1H, m), 1.48 (9H, s), 0.96
(6H, m). 13C-NMR (CDCl3, 100 MHz) δ 174.4, 156.4, 144.0, 141.3, 127.6, 127.0, 125.1,
119.9, 81.1, 67.3, 66.7, 47.6, 47.3, 40.7, 31.6, 28.1, 19.3, 18.4. HR-ESI: [M+H]+ cacl:
439.25913, found: 439.25892.
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Compound 2e. Yield 90%. 1H-NMR (CDCl3, 400 MHz) δ 7.76 (2H, d, J = 7.6), 7.61 (2H, d,
J = 7.6), 7.40 (2H, t), 7.31 (2H, m), 5.33 (1H, m), 4.38 (2H, m), 4.23 (1H, t), 3.32(1H, m),
3.20 (1H, m), 3.12 (1H, m),  2.80 (1H, m), 2.60 (1H, m), 1.77 (1H, m), 1.47 (9H, s), 1.42
(2H, m), 0.93 (6H, q). 13C-NMR (CDCl3, 100 MHz) δ 175.3, 156.4, 144.0, 141.3, 127.6,
127.0, 125.1, 119.9, 81.0, 66.7, 60.2, 47.3, 47.1, 40.8, 28.1, 24.9, 22.7, 22.3. HR-ESI:
[M+H]+ cacl: 453.27478, found: 453.27400.
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Compound 3a-1. Yield 86%. 1H-NMR (CDCl3, 400 MHz) (two rotomers) δ 7.76 (2H, d, J =
8), 7.59 (2H, t, J = 8), 7.40 (2H, m), 7.30 (2H, m), 5.89 & 5.78 (1H, s), 4.41 (2H, m), 4.35 &
3.99 (1H, m), 4.21 (1H, m), 3.71&3.63 (1H, m), 3.42-3.22 (3H, m), 2.22-2.10 (3H, m), 1.47
& 1.46 (9H, s), 1.42 (3H, d, J = 8), 0.98-0.90 (6H, m). 13C-NMR (CDCl3, 100 MHz) δ 174.2,
172.4, 171.3, 170.7, 156.5, 144.0, 143.8, 141.3, 141.2, 127.7, 127.6, 127.0, 126.9, 125.0,
124.9, 119.9, 119.8, 82.5, 81.6, 66.8, 66.7, 56.45, 56.2, 47.2, 46.8, 43.2, 41.8, 41.2, 39.9,
27.9, 27.8, 25.6, 25.5, 22.7, 22.6, 16.4, 14.4. HR-ESI: [M+H]+ cacl:493.26970,
found:493.26822.
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Compound 3a-2. Yield 80%. 1H-NMR (CDCl3, 400 MHz) (two rotomers) δ 7.76 (2H, d, J =
7.2), 7.59 (2H, t, J = 7.2), 7.40 (2H, t), 7.30 (2H, t), 5.93 & 5.72 (1H, s), 4.41 (2H, m), 4.35 &
4.07 (1H, m), 4.21 (1H, m), 3.70-3.24 (4H, m), 2.31 (2H, m),  1.47 & 1.46 (9H, s), 1.42 (3H,
d, J=7.2), 1.17&1.08 (3H, t). 13C-NMR (CDCl3, 100 MHz) δ 175.4, 173.7, 171.5, 170.7,
156.6, 156.5, 144.0, 143.8, 141.3, 141.2, 127.7, 127.6, 127.0, 126.9, 125.1, 124.9, 119.9,
119.8, 82.5, 81.6, 66.8, 56.3, 55.9, 47.21, 47.17, 46.4, 43.4, 41.0, 39.9, 27.9, 27.8, 26.9, 26.4,
16.3, 14.5, 9.4. HR-ESI: [M+H]+ cacl: 467.25405, found: 467.25483.
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Compound 3b. Yield 83%. 1H-NMR (CDCl3, 400 MHz) (two rotomers) δ 7.77 (2H, d, J =
8), 7.56 (2H, m), 7.40 (2H, t), 7.30-7.27 (3H, m), 7.24-7.11 (4H, m), 5.73 & 5.50 (1H, m),
4.41 (2H, t), 4.37  (2H, d, J = 8), 4.18 (1H, t, J = 8), 3.71 (1H, m), 3.60-2.95 (6H, m), 2.53
(1H, m),  2.18 (2H, m), 1.50 & 1.44 (9H, s), 1.08 (3H, t). 13C-NMR (CDCl3, 100 MHz) δ
174.0, 170.0, 156.4, 143.8, 141.3, 138.5, 129.2, 128.5, 127.7, 127.1, 126.6, 124.9, 119.9,
82.1, 66.6, 63.6, 49.3, 47.1, 39.1, 34.4, 27.9, 26.5, 9.5. HR-ESI: [M+H]+ cacl: 543.28535,
found: 543.28631.
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Compound 3c. Yield 68%. 1H-NMR (CDCl3, 400 MHz) (two rotomers) δ 8.12 (1H, d, J =
8), 7.77 (2H, d), 7.54 (2H, d, J = 8), 7.46 (1H, d, J=8), 7.61-7.48 (4H, m), 7.42-7.26 (10H,
m), 7.23-7.18 (1H, m), 5.55 (1H, m), 5.22 & 5.12 (2H, m), 4.33(2H, m), 4.16 (1H, m), 4.01
(1H, m), 3.66(2H, m), 3.57-3.39 (3H, m),  3.17 (2H, m), 2.67 (1H, m), 2.45 (2H, m), 1.66
N
H
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O
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(9H, s), 1.15 & 1.13 (9H, s). 13C-NMR (CDCl3, 100 MHz) δ 171.9, 170.6, 156.3, 149.5,
143.9, 143.8, 141.3, 135.3, 130.2, 128.7, 128.5, 128.3, 127.7, 127.0, 125.0, 124.5, 124.05,
124.00, 122.7, 119.9, 118.6, 116.8, 115.4, 83.7, 73.1, 67.5, 66.7, 62.2, 57.9, 49.7, 47.2, 39.7,
34.3, 28.2, 27.4, 24.1. HR-ESI: [M+H]+ cacl: 788.39055, found: 788.39110.
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Compound 3e-1. Yield 88%. 1H-NMR (CDCl3, 400 MHz) (two rotomers) δ 7.76 (2H, d, J =
8), 7.60 (2H, t), 7.40(2H, m), 7.30 (2H, m), 5.97 & 5.81 (1H, t), 4.40-4.35 (2H, m), 4.43-4.21
(2H, m), 3.60 (1H, m), 3.36 (3H, m), 1.84-1.53 (3H, m),  1.48 & 1.46 (9H, s), 1.19 & 1.09
(3H, t),  0.97-0.92 (6H, m). 13C-NMR (CDCl3, 100 MHz) δ 175.8, 174.1, 171.6, 170.4,
156.5, 144..0, 143.8, 141.26, 141.23, 127.6, 127.5, 127.03, 129.96, 125.2, 124.9, 119.9,
119.8, 82.5, 81.8, 66.9, 66.7, 59.2, 58.2, 47.2, 46.9, 41.1, 39.8, 38.9, 38.0, 27.97, 27.91, 26.9,
26.5, 25.1, 24.7, 23.1, 22.7, 22.2, 22.1, 9.4. HR-ESI: [M+H]+ cacl: 509.30100, found:
509.30228.
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Compound 3e-2. Yield 88%. 1H-NMR (CDCl3, 400 MHz) (two rotomers) δ 7.76 (2H, d, J =
8), 7.61 (2H, m), 7.40 (2H, t), 7.30 (3H, m), 7.23-7.10 (4H, m), 5.94 & 5.72 (1H, m), 4.37-
4.15 (4H, m), 3.62-2.58 (8H, m), 1.83-1.60 (3H, m),  1.47 & 1.44 (9H, s),  0.94-0.90 (6H,
m). 13C-NMR (CDCl3, 100 MHz) δ 174.2, 172.6, 171.5, 170.3, 156.5, 144.0, 143.8, 141.3,
141.1, 128.5, 128.3, 127.7, 127.6, 127.1, 126.9, 126.2, 126.0, 125.2, 125.0, 119.9, 119.8,
82.6, 81.9, 66.9, 66.7, 59.3, 58.4, 47.2, 47.1, 40.9, 39.9, 38.8, 37.9, 35.6, 34.9, 31.3, 27.97,
27.91, 25.0, 24.8, 23.1, 22.7, 22.2, 22.0. HR-ESI: [M+H]+ cacl:585.33230, found:585.33123.
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Compound 4a-1. Yield 82%. 1H-NMR (CDCl3, 400 MHz) (two rotomers) δ 8.95 (1H, b),
7.75 (2H, d, J = 8),  7.56 (2H, d, J = 8), 7.40-7.27 (4H, m), 6.36 & 6.24 & 5.94 & 5.76 (1H,
s), 4.63-3.90 (4H, m), 3.69-2.99 (4H, m), 2.24-1.96 (3H, m), 1.51  & 1.38 (3H, m), 0.97-
0.88 (6H, m), 13C-NMR (CDCl3, 100 MHz) 175.2, 174.3, 157.2, 156.8, 143.9, 143.7, 141.2,
140.6, 130.2, 127.7, 127.1, 126.4, 125.1, 124.5, 119.9, 119.8, 67.2, 55.9, 47.08, 47.05, 43.5,
42.4, 41.6, 40.4, 39.8, 25.9, 25.8, 22.4, 22.3, 16.2, 14.3. HR-ESI: [M+H]+ cacl: 439.22275,
found: 439.22449.
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Compound 4a-2. Yield 85%. 1H-NMR (CD3OD, 400 MHz) (two rotomers) δ 7.77 (2H, d, J
= 8), 7.61 (2H, d, J = 8), 7.38-7.28 (4H, m), 4.37-4.17 (3H, m), 4.43-4.21 (2H, m), 3.50 (1H,
m), 3.08-2.83 (2H, m), 2.37 (2H, m),  1.44 & 1.26 (3H, m), 1.06 & 0.98 (3H, m). 13C-
NMR (CDCl3, 100 MHz) δ =175.2, 174.9, 156.6, 143.7, 141.2, 127.6, 127.0, 125.0, 119.9,
67.0, 55.7, 47.0, 43.3, 42.5, 40.6, 39.8, 26.9, 26.4, 23.2, 16.1, 14.3, 9.4, 9.2. HR-ESI: [M+H]+
cacl: 411.19145, found: 411.19304.
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Compound 4b. Yield 87%. 1H-NMR (CDCl3, 400 MHz) (two rotomers) δ 9.18 (1H, b), 7.76-
7.52 (4H, m), 7.39-7.07 (9H, m), 6.13 & 5.98 & 5.88 & 5.30 (1H), 4.57-4.13 (3H, m), 3.86-
3.09 (5H, m), 2.81-1.90 (4H, m), 1.09-0.92 (3H, m). 13C-NMR (CDCl3, 100 MHz) δ 176.1,
173.7, 156.1, 143.77, 143.72, 141.3, 137.8, 129.2, 128.7, 127.7, 127.0, 125.0, 119.9, 66.9,
63.2, 49.8, 47.1, 39.1, 34.3, 26.5, 9.4. HR-ESI: [M+H]+ cacl: 487.22275, found: 487.22406.
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Compound 4c. Yield 72%. 1H-NMR (CDCl3) (two rotomers) δ 8.12 (1H, s),  7.72 (2H, d, J
= 8),   7.34 (2H, d, J = 8), 7.29-7.17 (8H, m),  6.14 & 5.87 (1H), 4.45-3.85 (4H, m), 3.67
(2H, m), 3.53 (3H, m), 3.22 & 2.94 (2H, m), 2.73-2.29 (3H, m), 1.67 & 1.66(9H, s), 1.18 &
1.13 & 1.06 (9H, s). 13C-NMR (CDCl3, 100 MHz) δ 172.9, 169.3, 156.4, 149.5, 143.8, 141.2,
135.3, 130.2, 127.6, 127.0, 125.1, 124.6, 124.0, 122.7, 119.9, 118.6, 116.9, 115.4, 83.7, 66.9,
62.7, 57.9, 50.2, 47.1, 39.5, 34.3, 28.2, 27.4, 24.1. HR-ESI: [M+H]+ cacl: 698.34359, found:
698.34416.
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Compound 4d. Two steps yield is 56%. 1H-NMR (CD3OD, 400 MHz) (two rotomers) δ 7.76
(2H, d, J = 8), 7.60 (2H, d, J=8), 7.36 -7.26 (2H, m), 4.36-4.16 (3H, m), 3.93(1H, m), 3.58-
2.98 (4H, m), 2.47-2.22 (3H, m), 1.07(6H, m), 0.82 (3H, m). 13C-NMR (CDCl3, 100 MHz) δ
176.3, 175.5, 157.3, 143.9, 141.1, 127.4, 126.7, 124.7, 119.5, 66.4, 65.1, 39.0, 38.4, 27.7,
27.3, 26.8, 26.4, 25.8, 20.1, 18.7, 18.1, 18.0, 8.6, 8.4. HR-ESI: [M+H]+ cacl: 439.22275,
found: 439.22447.
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Compound 4e-1. Yield 87%. 1H-NMR (CDCl3, 400 MHz) (two rotomers) δ 8.01 (1H, b),
7.74 (2H, d, J=8), 7.56 (2H, d, J=8), 7.38-7.28 (4H, m), 6.37 & 6.21 & 5.99 & 5.84 (1H),
4.61-4.08 (4H, m), 3.66-2.92 (4H, m), 2.40 & 2.27 (2H, m), 1.99-1.57 (3H, m), 1.12 (3H, m),
0.94 (6H, m). 13C-NMR (CDCl3, 100 MHz) δ 176.3, 175.9, 175.1, 173.9, 157.1, 156.8, 143.7,
141.2, 127.7, 127.0, 125.0, 119.9, 67.1, 58.3, 50.9, 47.6, 47.1, 40.3, 39.7, 38.6, 37.7, 29.4,
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26.8, 26.5, 25.0, 24.7, 22.9, 22.7, 22.0, 21.9, 9.7, 9.4. HR-ESI: [M+H]+ cacl: 453.23840,
found: 453.23976.
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Compound 4e-2. Yield 78%. 1H-NMR (CDCl3, 400 MHz) (two rotomers) δ 7.75 (2H, d),
7.56 (2H, m), 7.39-7.08 (9H, m), 6.38 & 6.31 & 5.85 & 5.75 (1H), 4.48-4.11 (4H, m), 3.58 &
3.47 (1H, m), 3.33-3.23 (2H, m), 2.92 (3H, m), 2.66 & 2.29 (2H, m), 1.91-1.81 (2H, m), 1.47
(1H, m), 0.90 (6H, m). 13C-NMR (CDCl3, 100 MHz) δ 175.2, 174.5, 174.1, 173.3, 156.7,
143.8, 141.2, 140.8, 140.6, 128.5, 128.4128.3, 127.7, 127.6, 127.1, 126.1, 125.1, 124.4,
119.9, 67.1, 58.4, 57.8, 47.6, 47.0, 40.1, 39.8, 38.6, 37.7, 35.5, 34.8, 31.3, 24.9, 24.7, 23.1,
22.8, 22.2, 21.9. HR-ESI: [M+H]+ cacl: 529.26970, found: 529.27080.
6.1.4 Computer Modeling
Figure 6.2 Energy minimized (MM2) structure of AA4 is superimposed with p53 17-29
helical domain (yellow colored). AA4 is shown as stick presentation; three critical residues
(Phe19, Trp23, and Leu 26) in p53 responsible for binding to MDM2 are red colored.
6.1.5 Solid phase synthesis, purification and characterization of AApeptides
AApeptides were prepared on Knorr resin in peptide synthesis vessels on a Burrell
Wrist-Action shaker following stand Fmoc chemistry of solid phase peptide synthesis
protocol using synthesized AApeptide building blocks. Each coupling cycle included an
Fmoc deprotection using 20% Piperidine in DMF, and 4 h coupling of 1.5 equiv of
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AApeptide building blocks onto resin in the presence 2 equiv of DIC
(diisopropylcarbodiimide) /DhbtOH (3-4-Dihydro-3-hydroxy-4-oxo-1-2-3-benzotriazine) in
DMF. After desired sequences were assembled, they were transferred into a 4 ml vial and
cleaved from solid support in 74:24:2 TFA/CH2Cl2/triisopropylsilane for 2 h. Then solvent
was evaporated and then the residues were analyzed and purified on an analytical (1 ml/min)
and a preparative Dionex (20 ml/min) HPLC systems, respectively. Both HPLC had same
methods which were using 5% to 100% linear gradient of solvent B (0.1% TFA in
acetonitrile) in A (0.1% TFA in water) over 40 min, followed by 100% solvent B over 10
min. The desired fractions were eluted as single peaks at  95% purity. They were collected
and lyophilized. The molecular weights of AApeptides were obtained on Bruker AutoFlex
MALDI-TOF mass spectrometer using –cyano-4-hydroxy-cinnamic acid.
Figure 6.3 HPLC traces of crude AApeptides
AA1 AA2
AA4AA3
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Table 6.1 MALDI-TOF MS analysis of AApeptides
AApeptides Formula Mass calcd. Mass found
AA1 C50H76N10O9 961.20 984.70 (M + Na)+
AA2 C49H74N10O9 947.17 949.45 (M+H)+
AA3 C63H92N12O11 1193.48 1195.21 (M+H)+
AA4 C57H88N12O11 1117.38 1118.89 (M+H)+
6.1.6 ELISA Assay
GST-MDM2-1-150 and full-length His6-p53 were expressed in E. coli and affinity
purified under non-denaturing conditions. ELISA plates were incubated with 2.5 µg/ml His6-
p53 in phosphate buffered saline (PBS) for 16 hrs. After washing with PBS+0.1% Tween 20
(PBST), the plates were blocked with PBS+5% non-fat dry milk+0.1% Tween 20 (PBSMT)
for 0.5 hr. GST-HDM2 was mixed with inhibitors in PBSMT+10% glycerol+10 mM DTT
and added to the wells. The plates were washed with PBST after incubating for 1 hr at room
temperature, incubated with MDM2 antibody 4B2 in PBSMT for 1 hr, followed by washing
and incubation with HRP-rabbit-anti-mouse Ig antibody for 1 hr. The plates were developed
by incubation with TMB peroxidase substrate (KPL) and measured by absorbance at 450 nm.
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Figure 6.4 Inhibition of p53-MDM2 binding by AApeptides with ELISA assay
6.1.7 Assay for Enzyme Hydrolysis
AApeptide AA3 (1 mg/ml) was incubated with  0.1 mg/ml chymotrypsin (RT), trypsin
(RT), and pronase (37 oC)  in 100 mM pH 7.8 ammonium bicarbonate buffer for 12 h,
respectively. A modified conventional peptide P (RYVEVXOKILG, X = -
NHCH2CH2N(SO2Me)CH2CO-) was also incubated with the above enzymes as the control to
show enzymes are active. Then the reaction mixtures were analyzed by HPLC by comparing
their retention time and integration to those of the starting materials. The results show that the
conventional peptide was being digested in all of the above enzymes but AApeptide AA3 is
very resistant to proteolysis. No degradation has been observed. Interestingly, at 37 oC, a
doubling of the peaks for AA3 is observed. MS analysis proves the peaks are from same
AApeptide AA3 and thus represent conformers with tertiary amide cis/trans isomerization on
the backbone.
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Table 6.2 Analytical HPLC traces of AApeptide AA3 and conventional peptide P after
incubation with different enzymes
AApeptide 3 Conventional peptide P
RT + buffer RT + buffer
37 oC + buffer 37 oC + buffer
RT + buffer + Trypsin RT + buffer + Trypsin
RT + buffer + Chymotrypsin RT + buffer + Chymotrypsin
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37 oC + buffer + Pronase 37 oC + buffer + Pronase
6.2 Supporting Information for Chapter 3
6.2.1 General consideration
-amino acid esters and Rink amide resin (0.66 mmol/g, 200-400 mesh) were provided
by Chem-Impex International, Inc. All other reagents and solvents were purchased from either
Sigma-Aldrich or Fisher Scientific. The α-AApeptide building blocks were synthesized
following previously reported procedure. Lipidated α-AApeptides were prepared on a Rink
amide resin in peptide synthesis vessels on a Burrell Wrist-Action shaker using α-AApeptide
building blocks. The α-AApeptides were analyzed and purified on an analytical and a
preparative Waters HPLC system, respectively, and then dried on a Labcono lyophilizer.
Molecular weights of the lipidated α-AApeptides were identified on a Bruker AutoFlex
MALDI-TOF mass spectrometer.
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6.2.2 Synthesis of α-AApeptide Building Blocks
Figure 6.5 Synthesis of α-AApeptide building blocks. a) R1CH2COOH, DhBtOH/DIC,
overnight. b) Pd/C, H2, EtOAc, overnight.
All the procedures are same as the procedure in chapter 6.1.2
6.2.3 NMR and High Resolution Mass Data
N
OH
O
H
N
Fmoc
O
HN
Boc
7a. 61% for two steps. 1H-NMR (DMSO-d6, 500 MHz) δ = 7.84(m, 2H), 7.65-7.58(m, 2H),
7.36(m, 2H), 7.27(m, 2H),7.22(m, 2H), 7.16-7.10(m, 2H), 7.01(m, 1H), 6.77-6.72(s, 1H), 4.25-
4.14(m, 4H), 3.16-3.06(m, 3H), 2.88-2.78(m, 4H), 2.57(m, 1H), 2.16(m, 2H), 1.53(m, 2H),
1.32(s, 9H). 13C-NMR (CDCl3, 125 MHz) 173.26, 156.49, 143.79, 141.27, 129.18, 128.72,
127.73, 126.86, 125.06, 124.35, 119.98, 79.22, 66.95, 63.66, 49.77, 47.06, 40.07, 39.24, 34.37,
30.35, 28.38, 25.11. HR-ESI: [M+H]+ cal 616.30191, found 616.30191.
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N
OH
O
H
N
Fmoc
O
HN
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NH
Boc
7b. 67% for two steps. 1H-NMR (CDCl3, 500 MHz) δ =  7.74(m, 2H), 7.57(m,2H), 7.37(m,
2H), 7.28(m,2H), 5.92(s, 1H), 4.99-4.63(m, 2H), 4.36-4.04(m, 4H), 3.61-3.07(m, 8H), 2.37-
1.77(m,6H), 1.41-1.37(b,20), 0.82(m, 2H) 13C-NMR (CDCl3, 125 MHz) 173.92, 156.72,
156.27, 143.82, 141.26, 127.72, 127.07, 125.15, 119.98, 79.19, 67.07, 60.55, 48.19, 47.10,
40.11, 39.33, 31.93, 30.20, 29.70, 28.43, 25.40, 23.82, 14.12. HR-ESI: [M+H]+ cal 696.3734,
found 697.3819.
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2. 1H-NMR (CD3OH, 600MHz) δ = 8.05-7.85 (17H), 7.24-7.13 (25H), 4.60-4.31 (5H), 3.62-
2.32 (50H), 2.10-1.51 (14H), 1.23 (24H), 0.85 (3H). 13C-NMR (CD3OH, 125 MHz) δ =
75.51, 173.44, 171.68, 170.14, 161.68, 137.60, 136.85, 129.29, 128.97, 128.36, 126.81,
126.57, 62.37, 61.58, 39.28, 37.84, 35.71, 35.44, 33.99, 31.65, 30.16, 29.88, 29.35, 29.23,
29.04, 28.90, 25.67, 25.54, 22.86, 22.33, 13.13.
6.2.4 Solid phase synthesis, purification and characterization of lipidated α-
AApeptides
Lipidated α-AApeptides were prepared on a Rink amide resin in peptide synthesis
vessels on a Burrell Wrist-Action shaker following standard Fmoc chemistry protocol of solid
phase peptide synthesis using synthesized α-AApeptide building blocks. Each coupling cycle
included an Fmoc deprotection using 20% piperidine in DMF, and 8 h coupling of 1.5 equiv
of α-AApeptide building blocks onto resin in the presence 4 equiv of DIC
(diisopropylcarbodiimide) / DhbtOH (3-4-Dihydro-3-hydroxy-4-oxo-1-2-3-benzotriazine) in
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DMF. The lipidation was achieved on resin by capping the N-terminus of last α-AApeptide
building block with palmitic acid (hexadecanoic acid). Next, the resin was transferred into 4
mL vials and the lipidated α-AApeptides were cleaved from solid support in 50:48:2
TFA/CH2Cl2/triisopropylsilane overnight. Then solvent was evaporated and the residues were
analyzed and purified on an analytical (1 mL/min) and a preparative Waters (20 mL/min)
HPLC systems, respectively, using 5% to 100% linear gradient of solvent B (0.1% TFA in
acetonitrile) in A (0.1% TFA in water) over 40 min, followed by 100% solvent B over 10
min. The HPLC traces were detected at 215 nm. The desired fractions were collected and
lyophilized. The molecular weights of lipidated α-AApeptides (Figure S1 and Table S1) were
obtained on Bruker AutoFlex MALDI-TOF mass spectrometer using –cyano-4-hydroxy-
cinnamic acid.
Table 6.3 MALDI analysis of lipidated α-AApeptides
Lipidated α-
AApeptides
Yield (based on
loading of the resin)
molecular weight
(Actual)
molecular weight (found)
NA-75 17.8% 794.2 795.9 (M+H+)
NA-77 22.7% 862.2 863.8 (M+H+)
NB-119-1 13.5% 1081.4 1081.7 (M+H+)
NB-127 6.8% 1165.6 1167.0 (M+H+)
NB-119-2 11.2% 1632.1 1632.2 (M+H+)
NB-119-3 8.3% 1393.8 1394.0 (M+H+)
NB-123 6.2% 1336.8 1137.0 (M+H+)
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Figure 6.6 The structures of synthesized lipidated α-AApeptides
6.2.5 Antimicrobial assays
The microbial organisms used were E. coli (JM109), B. subtilis (BR151), multi-drug resistant S.
epidermidis (RP62A), C. albicans (ATCC 10231), Vancomycin-resistant E. faecalis (ATCC 700802),
Methicillin-resistant S. aureus (ATCC 33592), K. pneumoniae (ATCC 13383), multi-drug resistant P.
aeruginosa ATCC 27853. The minimum inhibitory concentration (MIC) is the lowest concentration
that completely inhibits the growth of bacteria in 24 h. The highest concentration tested for
antimicrobial activity was 50 µg/mL. The antimicrobial activities of the lipidated α-AApeptides were
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determined in a sterile 96 -well plates by broth micro-dilution method. Bacterial cells and fungi 1 were
grown overnight at 37 ºC in 5 mL medium, after which a bacterial suspension (approximately 106
CFU/mL) or fungal suspension Candida albicans (ATCC 10231) (approximately 103 CFU/mL) in
Luria broth or trypticase soy was prepared. Aliquots of 50 µL bacterial or fungal suspension were added
to 50 µL of medium containing the α-AApeptides for a total volume of 100 µL in each well. The α-
AApeptides were prepared in PBS buffer in 2 –fold serial dilutions, with the final concentration range
of 0.5 to 50 µg/mL. Plates were then incubated at 37 ºC for 24 h (for bacteria) or 48 h (for Candida
albicans (ATCC 10231). The lowest concentration at which complete inhibition of bacterial growth
(determined by a lack of turbidity) is observed throughout the incubation time is defined as the
minimum inhibitory concentration (MIC). The experiments were carried out independently three times
in duplicates.
6.2.6 Antimicrobial assays
A double staining method with DAPI (4’,6-Diamidino-2-phenylindole dihydrochloride,
Sigma, >98%) and PI (Propidium iodide, Sigma) as fluorophores was used to visualize and differentiate
the viable from the dead E. coli or B. subtilis cells. DAPI as a double stranded DNA binding dye, stains
all bacterial cells irrespective of their viability. Whereas Ethidium derivatives such as propidium iodide
(PI) is capable of passing through only damaged cell membranes  and  intercalates with the nucleic
acids of injured and dead cells to form a bright red fluorescent complex. The cells were first stained
with PI and then with DAPI. Bacterial cells were grown until they reached mid-logarithmic phase and
then they (~2 × 106 cells) were incubated with the lipo-α-AApeptide at the concentration of 2× MIC (10
µg/ml) for 2 h. Then the cells were pelleted by centrifugation at 3000g for 15 min in an eppendorf
microcentrifuge. The supernatant was then decanted and the cells were washed with 1× PBS several
times and then incubated with PI (5 µg/ml) in dark for 15 min at 0 oC. The excess PI was removed by
washing the cells with 1× PBS several times. Then the cells were incubated with DAPI (10 µg/ml in
water) for 15 mins in dark at 0 oC. The DAPI solution was removed and cells were washed with 1× PBS
several times. Controls were performed following the exact same procedure for bacteria without the
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addition of lipo-α-AApeptides. The bacterial cells were then visualized by using the Zeiss Axio Imager
Z1optical microscope with an oil-immersion objective (100×).
6.3 Supporting Information for Chapter 4
6.3.1 General consideration
-amino acid esters and Knorr resin (0.66 mmol/g, 200-400 mesh) were provided by
Chem-Impex International, Inc. All other reagents and solvents were purchased from either
Sigma-Aldrich or Fisher Scientific. NMR spectra of intermediates and AApeptide building
blocks were obtained on a Varian Inova 400 instrument. AApeptides were prepared on Knorr
resin in peptide synthesis vessels on a Burrell Wrist-Action shaker. The AApeptides were
analyzed and purified on an analytical and a preparative Dionex HPLC systems, respectively,
and then dried by a Labcono lyophilizer.
6.3.2 Solid phase synthesis, purification and characterization of AApeptides
The synthesis of AApeptides was carried out following our reported procedures on the
solid phase (Fig.6.7). In brief, α-AApeptides 1 and 2 were obtained by incorporating the α-
AApeptide building block directly in the synthesis. γ-AApeptides 3-7 were synthesized by
using alloc protected γ-AApeptide building blocks. Each coupling cycle included an Fmoc
deprotection using 20% Piperidine in DMF, and 4 h coupling of 1.5 equiv of AApeptide
building blocks onto resin in the presence 2 equiv of DIC (diisopropylcarbodiimide) /DhbtOH
(3-4-Dihydro-3-hydroxy-4-oxo-1-2-3-benzotriazine) in DMF. The formyl group on the N-
terminus of methionine and norleucine in the sequences was added following a published
protocol. Briefly, isobutyl chloroformate and formic acid were mixed at 1:1 ratio in DCM, and
then cooled down to at 0 °C, to which 1 equiv. NMM (N-methylmorpholine) was added. The
resulting solution was added to resin and allowed to react for two hours. The procedure was
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repeated twice. The AApeptides were obtained by HPLC purification after cleavage from solid
support by TFA. After desired sequences were assembled, they were transferred into a 4 ml
vial and cleaved from solid support in 74:24:2 TFA/CH2Cl2/triisopropylsilane for 2 h. Then
solvent was evaporated and then the residues were analyzed and purified on an analytical (1
ml/min) and a preparative Dionex (20 ml/min) HPLC systems, respectively. Both HPLC had
same methods which were using 5% to 100% linear gradient of solvent B (0.1% TFA in
acetonitrile) in A (0.1% TFA in water) over 40 min, followed by 100% solvent B over 10 min.
The desired fractions were eluted as single peaks at  95% purity. They were collected and
lyophilized.
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Figure 6.7 a, synthesis of α-AApeptides 1 and 2; b, synthesis of γ-AApeptides 3-7
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6.3.1 NMR Data
Compound 1. 1H-NMR (CD3OD, 400MHz) δ = 8.08 (1H, d), δ = 7.21(5H, m), δ = 4.43(1H,
m), δ =4.22(1H, m), δ =3.41-3.04(5H, m), δ =2.86-1.84(10H, m), δ = 1.56-1.42(3H, m), δ =
0.89(6H)
13C-NMR (CD3OD, 100MHz) δ =174.7, 172.6, 172.1, 162.4, 138.2, 128.9, 128.1, 126.3, 62.6,
51.0, 48.7, 37.3, 34.1, 33.9, 31.1, 30.9, 29.6, 27.5, 21.3, 13.8
Compound 2. 1H-NMR (CD3OD, 400MHz) δ =8.06(1H, m), δ =7.28-7.15(5H, m), δ
=4.22(2H, m), δ =3.44-3.06(4H, m), δ =2.62-2.22(2H, m), 1.93-1.30(9H, m), δ =0.90-
0.78(11H, m)
13C-NMR (CD3OD, 100MHz) δ =176.2, 174.1, 163.8, 139.7, 130.5, 129.6, 127.8, 64.0, 53.5,
50.3, 38.7, 35.6, 35.5, 32.9, 32.5, 28.9, 23.3, 22.8, 22.7, 14.3
Compound 3. 1H-NMR (CD3OD, 400MHz) δ =8.08(1H, d), δ =7.25-7.13(5H, m), δ =4.46-
3.29(5H, m), δ =2.91-2.41(6H, m), δ = 2.13-1.81(5H, m), δ =1.63(1H, m), δ =1.43(1H, m), δ
=1.23(1H, m), δ =85(7H, m)
13C-NMR (CD3OD, 100MHz) δ = 174.6, 174.1, 172.4, 171.9, 162.4, 141.1, 128.1, 128.0,
125.6, 52.8, 51.4, 50.7, 45.9, 40.8, 34.6, 31.4, 30.7, 29.7, 24.5, 22.3, 20.6, 13.8
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Compound 4. 1H-NMR (CD3OD, 400MHz) δ =8.07(1H, d), δ =7.25-7.14(5H, m), δ =4.30-
3.88(4H, m), δ =3.45-3.29(2H, m), δ = 2.87-2.48(4H, m), δ =1.74-1.20(9H, m), δ =0.92-
0.82(9H, m)
13C-NMR (CD3OD, 100MHz) δ =174.5, 174.0, 172.6, 171.8, 162.2, 141.0, 128.0, 125.6, 52.8,
52.3, 50.7, 50.2, 45.9, 40.8, 34.7, 31.5, 30.7, 27.7, 24.4, 21.9, 20.6, 12.8
Compound 5. 1H-NMR (CD3OD, 400MHz) δ =8.06(1H, d), δ =7.47-7.45(2H, m), δ =7.34-
7.33(3H, m), δ =4.47(3H, m), δ =4.07-3.93(3H, m), δ =3.08(2H, d), δ =2.48-1.17(9H, m), δ
=0.86(6H, m)
13C-NMR (CD3OD, 100MHz) δ =172.1, 171.9, 162.3, 130.8, 129.5, 128.1, 128.0, 57.5, 52.7,
51.4, 49.5, 45.4, 40.6, 31.3, 29.5, 24.4, 22.2, 20.7, 13.7
Compound 6. 1H-NMR (CD3OD, 400MHz) δ =8.08(1H, d), δ =7.29-7.21(5H, m), δ =4.50-
3.29(8H, m), δ =2.47(2H, m), δ =2.05-1.21(8H, m), δ =0.86(6H, m)
13C-NMR (CD3OD, 100MHz) δ =173.6, 172.9, 171.6, 162.3, 134.8, 129.0, 128.1, 126.4, 53.2,
51.3, 50.5, 46.1, 41.0, 39.8, 31.2, 29.7, 24.5, 22.3, 20.7, 13.8
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Compound 7. 1H-NMR (CD3OD, 400MHz) δ =8.07(1H, d), δ =7.29-7.20(5H, m), δ =4.35-
3.34(8H, m), δ =1.76-1.17(9H, m), δ =0.86(9H, m)
13C-NMR (CD3OD, 100MHz) δ =173.6, 172.6, 171.6, 162.2, 134.7, 128.9, 128.1, 126.4, 53.2,
52.3, 50.9, 40.9, 39.5, 31.4, 27.7, 24.4, 22.4, 21.9, 20.6, 12.8
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APPENDIX A 1H AND 13C NMR SPECTROSCOPY FOR COMPOUNDS
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